AD not in-‘soluble’ after all? Street likes Inmune’s bet on next-gen TNF July 14, 2020 By Randy Osborne No Comments Inmune Bio Inc. CEO Raymond Tesi told BioWorld his firm is taking an “oncology-style” approach to Alzheimer’s disease (AD) as the firm tests next-generation tumor necrosis factor (TNF) inhibitor XPro-1595 against neuroinflammation.Read More